VICKtOrY Program for New Cancer Medicines
VICKtOrY Early Clinical Trials Consortium
['FUNDING_OTHER'] · YALE UNIVERSITY · NIH-11093390
This program helps find new cancer medicines by matching treatments to a patient's unique tumor biology.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11093390 on ClinicalTrials.gov |
What this research studies
We are working to develop new cancer treatments that are more personalized than traditional approaches. This involves carefully looking at the unique genetic and biological makeup of each patient's tumor. By using advanced tests, we aim to identify patients who are most likely to benefit from specific new medicines. This approach allows us to design smarter clinical trials, focusing on smaller groups of patients to find the most effective treatments faster. Our goal is to improve outcomes for patients by matching them with the right therapy from the start.
Who could benefit from this research
Good fit: Patients with cancer who are seeking new treatment options and are open to advanced molecular testing may be ideal candidates.
Not a fit: Patients whose tumors do not have specific molecular markers targeted by the new agents being developed may not directly benefit from these particular early-phase opportunities.
Why it matters
Potential benefit: If successful, this program could lead to more effective and personalized cancer treatments with better outcomes for patients.
How similar studies have performed: This program builds upon a growing understanding that tailoring cancer treatments to individual tumor biology can improve patient responses, a concept supported by successes in targeted therapies.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LORUSSO, PATRICIA M. — YALE UNIVERSITY
- Study coordinator: LORUSSO, PATRICIA M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents